Clinical Trial Update: Role of Intralipid in Management of Organophosphorus Poisoning [Phase 2, Phase 3]

View source ↗

Summary

The Phase 2/Phase 3 clinical trial NCT04393103 evaluating intravenous lipid emulsion (Intralipid) for organophosphate poisoning has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Organophosphate Poisoning

Drugs mentioned

• Intralipid (intravenous lipid emulsion)

Snippet

Sponsor: Amani Hassan Abdel-Wahab | Conditions: Organophosphorus Poisoning | Phase 2, Phase 3 | Status: WITHDRAWN